Shalin Jani
Solaris Pharma Receives FDA Approval for Fluocinolone Acetonide Topical Oil, 0.01% (Body Oil)
Solaris Pharma Receives FDA Approval for Fluocinolone Acetonide Topical Oil, 0.01% (Body Oil)Solaris Pharma Corporation located Bridgewater, New Jersey
Solaris Pharma Receives FDA Approval for Fluocinolone Acetonide Topical Oil, 0.01% (Scalp Oil)
Solaris Pharma Corporation located Bridgewater, New Jersey announces the final approval from U.S Food and Drug Administration for its
Solaris Pharma Receives FDA Approval for Fluocinolone Acetonide Oil, 0.01% (Ear Drops)
Solaris Pharma Corporation located Bridgewater, New Jersey announces the final approval from U.S Food and Drug Administration for its
Solaris Pharma Receives FDA Approval for Acyclovir Ointment USP, 5%
Solaris Pharma Corporation located Bridgewater, New Jersey announces the final approval from U.S Food and Drug Administration on for
Solaris Pharma Receives FDA Approval for Clindamycin Phosphate Gel USP, 1% (Once-A-Day)
Solaris Pharma Corporation located Bridgewater, New Jersey announces the final approval from U.S Food and Drug Administration for its
Solaris Pharma Receives FDA Approval for First Generic Clindamycin Phosphate Topical Gel, 1%
BRIDGEWATER, N.J., Aug. 23, 2021 (GLOBE NEWSWIRE) — Solaris Pharma Corporation (“Solaris” or the “Company”) announced today that the
Solaris Pharma Announces Launch of Clindamycin Phosphate Gel USP, 1% in 30 g and 60 g Tubes
Solaris Pharma Corporation located in Bridgewater, New Jersey is pleased to announce the launch of Clindamycin Phosphate Gel USP,
Solaris Pharma Receives FDA Approval for Clobetasol Propionate Cream USP, 0.05%
Solaris Pharma Corporation located in Bridgewater, New Jersey announces final approval from U.S Food and Drug Administration for its
Solaris Pharma Receives FDA Approval for Clindamycin Phosphate Gel USP, 1% (Twice-A-Day)
Solaris Pharma Corporation located Bridgewater, New Jersey announces the final approval from U.S Food and Drug Administration for
Solaris Pharma Receives FDA Approval for Tazarotene Gel, 0.05% and 0.1%
Solaris Pharma Corporation is pleased to announce the product approval of Tazarotene Gel, 0.05% and 0.1%.
Solaris launches generic Briviact
Solaris has announced the launch of brivaracetam tablets, a generic version of UCB’s branded epilepsy medication Briviact.
The